Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorHannah Harris

About this trial

This outpatient study examines how inhaled cannabis, combustible or vaporized, alters lung health and breath biomarkers compared to a tobacco cigarette.

Eligibility criteria

Qualifiers

English-speaking,

Literate adults,

Male or female,

Between the ages of 18 and 55,

Disqualifiers

Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,

Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),

Existing or significant lung health problems that could interfere with the study,

Current or history of major psychiatric disorder that would limit the participant's ability to participate in the study (e.g., bipolar disorder),

Trial design

Treatments tested in this trial

  • Cannabis (THC)
  • Tobacco Cigarette

Treatment groups

12 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Hannah Harris

Lead sponsor

University of Kentucky

Sponsor institution